| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
RGS Stock Overview
Regeneus Ltd, a clinical-stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, and neuropathic pain and dermatology diseases in Australia.
Regeneus Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.06 |
| 52 Week High | AU$0.094 |
| 52 Week Low | AU$0.041 |
| Beta | 0.26 |
| 1 Month Change | 30.44% |
| 3 Month Change | 7.14% |
| 1 Year Change | -21.05% |
| 3 Year Change | -36.84% |
| 5 Year Change | -52.00% |
| Change since IPO | -77.78% |
Recent News & Updates
Shareholder Returns
| RGS | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 7.1% | -0.6% | -0.5% |
| 1Y | -21.1% | -8.7% | -12.2% |
Return vs Industry: RGS underperformed the Australian Biotechs industry which returned -8.7% over the past year.
Return vs Market: RGS underperformed the Australian Market which returned -12.2% over the past year.
Price Volatility
| RGS volatility | |
|---|---|
| RGS Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 9.9% |
| 10% most volatile stocks in AU Market | 16.6% |
| 10% least volatile stocks in AU Market | 4.4% |
Stable Share Price: RGS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: RGS's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Karolis Rosickas | https://regeneus.com.au |
Regeneus Ltd, a clinical-stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, and neuropathic pain and dermatology diseases in Australia. Its lead platform technology includes Progenza, a cryopreserved multi-synergistic therapy for the treatment of osteoarthritis and neuropathic pain. The company also develops Sygenus for the treatment of skin wound healing.
Regeneus Fundamentals Summary
| RGS fundamental statistics | |
|---|---|
| Market Cap | AU$18.39m |
| Earnings (TTM) | -AU$4.35m |
| Revenue (TTM) | AU$871.28k |
21.1x
P/S Ratio-4.2x
P/E RatioIs RGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGS income statement (TTM) | |
|---|---|
| Revenue | AU$871.28k |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$871.28k |
| Other Expenses | AU$5.22m |
| Earnings | -AU$4.35m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.014 |
| Gross Margin | 100.00% |
| Net Profit Margin | -499.18% |
| Debt/Equity Ratio | 52.8% |
How did RGS perform over the long term?
See historical performance and comparisonValuation
Is RGS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RGS?
Other financial metrics that can be useful for relative valuation.
| What is RGS's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | AU$18.39m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 20.7x |
| Enterprise Value/EBITDA | -3.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does RGS's PS Ratio compare to its peers?
| RGS PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.1x | ||
1AD AdAlta | 4.4x | n/a | AU$17.3m |
PAB Patrys | 15.6x | n/a | AU$43.2m |
DXB Dimerix | 9x | n/a | AU$40.1m |
BDX BCAL Diagnostics | 27.3x | n/a | AU$16.6m |
RGS Regeneus | 21.1x | n/a | AU$18.4m |
Price-To-Sales vs Peers: RGS is expensive based on its Price-To-Sales Ratio (21.1x) compared to the peer average (14.1x).
Price to Earnings Ratio vs Industry
How does RGS's PE Ratio compare vs other companies in the AU Biotechs Industry?
Price-To-Sales vs Industry: RGS is expensive based on its Price-To-Sales Ratio (21.1x) compared to the Australian Biotechs industry average (21.1x)
Price to Sales Ratio vs Fair Ratio
What is RGS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 21.1x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate RGS's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of RGS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RGS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RGS's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RGS's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Regeneus forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
15.7%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Regeneus has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of RGS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Regeneus competitive advantages and company strategy can generally be found in its financial reports archived here.
Past Performance
How has Regeneus performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
1.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RGS is currently unprofitable.
Growing Profit Margin: RGS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RGS is unprofitable, but has reduced losses over the past 5 years at a rate of 1.9% per year.
Accelerating Growth: Unable to compare RGS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RGS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).
Return on Equity
High ROE: RGS has a negative Return on Equity (-181.9%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Regeneus's financial position?
Financial Health Score
3/6Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: RGS's short term assets (A$2.7M) exceed its short term liabilities (A$2.0M).
Long Term Liabilities: RGS's short term assets (A$2.7M) exceed its long term liabilities (A$47.6K).
Debt to Equity History and Analysis
Debt Level: RGS has more cash than its total debt.
Reducing Debt: Insufficient data to determine if RGS's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RGS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: RGS has less than a year of cash runway if free cash flow continues to grow at historical rates of 9.4% each year.
Discover healthy companies
Dividend
What is Regeneus's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RGS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RGS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RGS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RGS's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RGS has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
1.7yrs
Average management tenure
CEO
Karolis Rosickas
1.67yrs
Tenure
AU$658,298
Compensation
Mr. Karolis Rosickas serves as Chief Executive Officer at Regeneus Ltd since November 2, 2020. He is an experienced executive and healthcare entrepreneur with business experience in healthcare, technology...
CEO Compensation Analysis
Compensation vs Market: Karolis's total compensation ($USD446.85K) is above average for companies of similar size in the Australian market ($USD281.90K).
Compensation vs Earnings: Insufficient data to compare Karolis's compensation with company performance.
Leadership Team
Experienced Management: RGS's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
Experienced Board: RGS's board of directors are considered experienced (7.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: RGS insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Regeneus Ltd's employee growth, exchange listings and data sources
Key Information
- Name: Regeneus Ltd
- Ticker: RGS
- Exchange: ASX
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$18.386m
- Shares outstanding: 306.44m
- Website: https://regeneus.com.au
Location
- Regeneus Ltd
- 2 Paddington Street
- Paddington
- New South Wales
- 2021
- Australia
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/03 00:00 |
| End of Day Share Price | 2022/07/01 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.